184 related articles for article (PubMed ID: 23686402)
41. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Esteban E; González de Sande L; Fernández Y; Corral N; Fra J; Muñiz I; Vieitez JM; Palacio I; Fernández JL; Estrada E; Lacave AJ;
Ann Oncol; 2003 Nov; 14(11):1640-7. PubMed ID: 14581272
[TBL] [Abstract][Full Text] [Related]
42. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
Gonçalves A; Viret F; Ciccolini J; Genre D; Gravis G; Giovanini M; Camerlo J; Catalin J; Maraninchi D; Viens P
Clin Cancer Res; 2003 Jan; 9(1):102-8. PubMed ID: 12538457
[TBL] [Abstract][Full Text] [Related]
43. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
[TBL] [Abstract][Full Text] [Related]
45. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
46. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
[TBL] [Abstract][Full Text] [Related]
47. Generic docetaxel chemotherapy induced skin toxicities in breast cancer patient.
Elalami I; Ichou M
Pan Afr Med J; 2016; 24():164. PubMed ID: 27826363
[No Abstract] [Full Text] [Related]
48. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
[TBL] [Abstract][Full Text] [Related]
49. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
[TBL] [Abstract][Full Text] [Related]
50. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Wenzel C; Locker GJ; Schmidinger M; Rudas M; Taucher S; Gnant MF; Jakesz R; Steger GG
Anticancer Drugs; 2002 Jan; 13(1):67-74. PubMed ID: 11914643
[TBL] [Abstract][Full Text] [Related]
51. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
[TBL] [Abstract][Full Text] [Related]
52. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
De Boer RH; Kotasek D; White S; Koczwara B; Mainwaring P; Chan A; Melara R; Ye Y; Adewoye AH; Sikorski R; Kaufman PA
Breast Cancer Res Treat; 2012 Aug; 135(1):241-52. PubMed ID: 22872523
[TBL] [Abstract][Full Text] [Related]
53. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
[TBL] [Abstract][Full Text] [Related]
54. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
[TBL] [Abstract][Full Text] [Related]
55. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
[TBL] [Abstract][Full Text] [Related]
56. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
[TBL] [Abstract][Full Text] [Related]
57. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
58. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
[TBL] [Abstract][Full Text] [Related]
59. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
[TBL] [Abstract][Full Text] [Related]
60. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
Miller KD; McCaskill-Stevens W; Sisk J; Loesch DM; Monaco F; Seshadri R; Sledge GW
J Clin Oncol; 1999 Oct; 17(10):3033-7. PubMed ID: 10506597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]